PARP抑制剂在放疗联合免疫治疗非小细胞肺癌的研究进展

Progress of PARP inhibitors in radiotherapy combined with immunotherapy for NSCLC

放疗是非小细胞肺癌(NSCLC)治疗的传统手段,免疫检查点抑制(ICB)是近年来治疗NSCLC的重大突破。继PACIFIC研究之后,多个放疗联合ICB的临床研究相继开展,取得了较好的成果,但NSCLC的疗效仍有待进一步提高。聚腺苷酸二磷酸核糖聚合酶1(PARP1)可能是增加放疗联合ICB疗效的一个靶点。研究表明,PARP抑制剂与放疗和ICB联合可以发挥协同作用。本文从PARP抑制剂治疗NSCLC的机制、放疗联合ICB的现状、PARP抑制剂联合放疗与ICB的机制及应用等方面,对PARP抑制剂在放疗联合ICB治疗NSCLC的研究进展进行阐述,以评估联合治疗在NSCLC治疗中的潜力,为NSCLC临床试验的开展提供一定的参考。

Radiotherapy is the traditional means of treatment for non-small cell lung cancer(NSCLC),and immune checkpoint blockade(ICB)is a major breakthrough in the treatment of NSCLC in recent years.Following the PACIFIC study,several clinical studies of radiotherapy combined with ICB have been carried out successively and achieved better results,but the efficacy of NSCLC still needs to be further improved.Poly ADP-ribose polymerase 1(PARP1)may be a target to increase the efficacy of radiotherapy combined with ICB.Studies have shown that PARP inhibitors can exert synergistic effects in combination with radiotherapy and ICB.In this paper,we describe the research progress of PARP inhibitors in radiotherapy combined with ICB in the treatment of NSCLC from the mechanism of PARP inhibitors in the treatment of NSCLC,the current status of radiotherapy combined with ICB,and the mechanism and application of PARP inhibitors in radiotherapy combined with ICB in the treatment of NSCLC,in order to assess the potential of the combination therapy in the treatment of NSCLC,and to provide some references for the development of clinical trials in NSCLC.